Astatine-211 alpha therapy
A rare alpha-emitting halogen that can be attached to antibodies and small molecules like iodine, tested in leukaemia conditioning and brain and ovarian cancer.
Overview
Astatine-211 is an alpha emitter with a 7.2-hour half-life that behaves chemically like iodine, so it can label antibodies and small molecules by radiohalogenation. Its short range and high energy suit micrometastatic and disseminated disease; academic programmes in Gothenburg, Seattle and Japan have tested At-211 antibodies in ovarian cancer and as anti-CD45 conditioning before transplant, and At-211 PSMA and MABG agents are in early trials. Production requires a cyclotron with alpha beams, limiting supply to a few centres.
- PSMA / SSTR-positive cell
How it works
At-211 is produced by bombarding bismuth with alpha particles, labelled to a targeting molecule, and delivers high linear-energy-transfer alpha particles over a few cell diameters.
- Alpha emission kills with few decays and overcomes resistance
- Iodine-like chemistry fits existing tracers
- Short half-life limits residual dose
- Very limited production capacity
- Short half-life constrains logistics
- Early clinical stage
Dependencies
Open the dependency map →Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Latest papers
topQuery for this technology: (TITLE:"Astatine-211 alpha therapy" OR ABSTRACT:"Astatine-211 alpha therapy") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Astatine-211 alpha therapy, not a curated reading list.
Similar pages
not linked directly; found by shared links- InstitutionQST Hospital (National Institutes for Quantum Science and Technology)
Shares Astatine-211, Targeted alpha therapy, Prostate cancer.
- CompanyARTBIO
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
- CompanyIBA (Ion Beam Applications)
Shares Medical cyclotrons, hot cells, and synthesis modules, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- InstitutionOslo University Hospital, The Norwegian Radium Hospital
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
- IsotopeCarbon-11
Shares Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Prostate cancer.
- CompanyAriceum Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyRatio Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- IdeaPretargeted alpha radioimmunotherapy
Shares Astatine-211, Targeted alpha therapy.